Latest Series C+ Funding Rounds
Later-stage rounds, from Series C onwards, for companies expanding products, distribution and operations.
- Rounds
- 420 All time
- Disclosed funding
- $108.3B 379 disclosed amounts
- Median round
- $120M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| L Loop provides an AI platform for logistics and supply-chain operations. | $95M | Series CSeries C+ | AI | United States | Investors | |
| P PlataCompany profile Provides digital banking services including credit cards, debit cards, and loans Provides digital banking services including credit cards, debit cards, and loans | $405M | Series CSeries C+ | Fintech | Mexico | Investors | |
| SF Slash FinancialCompany profile Offers business banking accounts, corporate credit cards, transfers, and crypto Offers business banking accounts, corporate credit cards, transfers, and crypto | $100M | Series CSeries C+ | Fintech | United States | Investors | |
| F FactoryCompany profile Develops an autonomous software-development platform for enterprise engineering teams. Develops an autonomous software-development platform for enterprise engineering teams. | $150M | Series CSeries C+ | AI | United States | Investors | |
| TB Terremoto BiosciencesCompany profile Develops highly targeted, small molecule medicines for cancer and rare diseases Develops highly targeted, small molecule medicines for cancer and rare diseases | $108M | Series CSeries C+ | Biotech | United States | Investors | |
| AT Alloy TherapeuticsCompany profile Drug discovery platforms and integrated development services for biotechnology and pharmaceutical partners. Drug discovery platforms and integrated development services for biotechnology and pharmaceutical partners. | $40M | Series ESeries C+ | Biotech | United States | Investors | |
| A AdcendoCompany profile Adcendo develops antibody-drug conjugates that deliver cancer drugs to tumor-associated targets, with clinical programs in solid tumors and soft tissue sarcoma. Adcendo develops antibody-drug conjugates that deliver cancer drugs to tumor-associated targets, with clinical programs in solid tumors and soft tissue sarcoma. | $75M | Series CSeries C+ | Biotech | Denmark | Investors | |
| C Develops medical devices for kidney stone treatment and removal | $40M | Series FSeries C+ | Healthtech | United States | Investors | |
| n Develops integrated optical interconnects for AI data centers | $80M | Series CSeries C+ | AI | United States | Investors | |
| C Provides AI-powered fine art logistics and storage services | Undisclosed | Series CSeries C+ | Logistics | France | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1Andreessen Horowitz (a16z)
Labelbox, Valon, Devoted Health
35rounds3led - 2Sequoia Capital
Blacksmith, Abby Care, Instinct
31rounds2led - 3Lightspeed
Enveda, Snorkel AI, Profound
28rounds3led - 4General Catalyst
Legora, Modal Labs, Varda
27rounds0led - 5Y Combinator (YC)
Blacksmith, Jeeves, Hubble Network
21rounds0led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.